We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Glythera Appoints Chief Scientific Officer and Strengthens SAB

Glythera Appoints Chief Scientific Officer and Strengthens SAB content piece image
Dr Robert Lutz
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Glythera Limited is pleased to announce the appointment of Dr Robert Lutz as Chief Scientific Officer. Dr Lutz will lead the advancement of Glythera’s portfolio of Antibody Drug Conjugates (ADCs) in the treatment of difficult-to-treat cancers. In addition, Glythera has appointed Dr Jon Roffey to the company’s Scientific Advisory Board (SAB).

With more than 25 years’ experience, Dr Lutz was previously Vice President of Translation Research and Development at ImmunoGen Inc., where he was responsible for all early-stage ADC development programs and gained further experience in directing the clinical pharmacology, biomarkers, pharmacology and toxicology departments. While at ImmunoGen, Dr Lutz was responsible for bringing eight of ImmunoGen’s candidate ADC products into development and included being the research lead for Kadcyla®.

Dr Jon Roffey joins Glythera’s SAB from Cancer Research Technology (CRT), Cancer Research UK’s Commercial Partnerships team, where he has been working since 2006, initially as medicinal chemistry group leader and, latterly, with responsibility for forging drug-discovery alliances between academia and industry. As a medicinal chemist by training, Dr Roffey has had active involvement in a wide variety of therapeutic areas, including the development of ADCs in cancer.

Dr Dave Simpson, Chief Executive Officer, Glythera, said: “Robert Lutz’s experience in ADC development will be a great asset as Glythera continues to develop our pipeline of cancer treatments. With Robert’s appointment as CSO, and the addition of Jon Roffey to our Scientific Advisory Board, we start 2018 in a strengthened position as developers of the very best novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat.”